Clinically, LEF1-inactivating mutations show a favorable trend towards overall survival in pediatric patients with T-ALL, which suggests that this molecular subtype of the disease may be more responsive than other subtypes to salvage therapy for relapsed T-ALL [87]. This evidence concerns the gene LEF1 and acute lymphoblastic leukemia.